Related references
Note: Only part of the references are listed.Mutations affecting mRNAsplicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
Frederik Damm et al.
BLOOD (2012)
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
Felicitas Thol et al.
BLOOD (2012)
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
Su-Jiang Zhang et al.
BLOOD (2012)
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Hideki Makishima et al.
BLOOD (2012)
Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML
Shinsuke Hirabayashi et al.
BLOOD (2012)
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
A. Tefferi et al.
LEUKEMIA (2012)
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients
T. L. Lasho et al.
LEUKEMIA (2012)
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
Victor Quesada et al.
NATURE GENETICS (2012)
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2012)
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
Ayalew Tefferi et al.
BLOOD (2011)
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients
A. Pardanani et al.
LEUKEMIA (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)